

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.wopto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,147	04/07/2006	You Moon Jeon	YPL0263US	7284
23413 CANTOR CO	7590 01/13/200 I BURN LUP	EXAMINER		
20 Church Stre		KOSACK, JOSEPH R		
22nd Floor Hartford, CT (06103		ART UNIT	PAPER NUMBER
, , , , ,			1626	
			NOTIFICATION DATE	DELIVERY MODE
			01/13/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

usptopatentmail@cantorcolburn.com

Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)		
	10/575,147	JEON ET AL.		
	Examiner	Art Unit		
	Joseph R. Kosack	1626		

	Joseph R. Kosack	1626	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress
THE REPLY FILED 03 December 2008 FAILS TO PLACE THIS	APPLICATION IN CONDITION F	OR ALLOWANCE.	
 X The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	the same day as filing a Notice of a replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
The period for reply expiresmonths from the mailing The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	date of the final rejection	n.
Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(FIRST REPLY WAS FI	ED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purposes of determining the period valued 77 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	on which the petition under 37 CFR 1.1: ension and the corresponding amount of hortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as
The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed w	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	of the date of appeal. Since
<u>AMENDMENTS</u>			
 The proposed amendment(s) filed after a final rejection, to the proposed amendment (s) filed after a final rejection, to the proposed amendment (s) They raise the issue of new matter (see NOTE below). 	nsideration and/or search (see NOT		cause
 (c) They are not deemed to place the application in bet appeal; and/or 	ter form for appeal by materially red	lucing or simplifying t	ne issues for
(d) ☐ They present additional claims without canceling a	corresponding number of finally reje	cted claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (I	PTOL-324).
5. Applicant's reply has overcome the following rejection(s):			
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 	owable if submitted in a separate, t	imely filed amendmer	it canceling the
 For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proving. 		be entered and an e	planation of
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea	l and/or appellant fail:	to provide a
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.
 The request for reconsideration has been considered bu See Continuation Sheet. 	does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information Disclosure Statement(s). (13. Other:	PTO/SB/08) Paper No(s).		
	/REI-TSANG SHIAO / Primary Examiner, Art U	nit 1626	
	Zxammor, rat o		

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 11. does NOT place the application in condition for allowance because: The comparative examples only show either TPP or [PD-QP-QP] used and not the two in combination. In Scheme 2 of van der Slot et all, it is detailed how when more than 1 equivalent of ligand is added to the rhodium complex that more than one ligand may coordinate to the rhodium atom with one ligand in a bidentate frashion while the other coordinates in a monodentate fashion. This shows that the quantity of ligand can be vided to achieve different results. Additionally, since the reaction is carried out normally with more than 1 equivalent of ligand, one of ordinary skill in the art would readily see that the mixed complex would be present, if not the dominant species. One of ordinary skill we would be invited to try to combine a monodentate ligand such as TPP, which as stated by Billig is the gold standard in hydroformylation with the bidentate ligand or and erSlot et al. In making the combination, the person of ordinary skill would try out various ratios of TPP to bidentate ligand to check out which is the best ratio for hydroformulation. Therefore, Applicant's claim of synergy is not necessarily unexpected since the various ratios of TPP to bidentate ligand of value of the value of v